Tag Archives: GILD

Top 10 High Tech Stocks To Buy For 2019

Johnson & Johnson (NYSE:JNJ), a staple in investor portfolios, has plenty of news for us to digest in its first-quarter earnings release.

In this episode of The Motley Fool’s Industry Focus: Healthcare, host Kristine Harjes is joined by Motley Fool contributor Todd Campbell to explain how Johnson & Johnson is doing and if it can overcome the threat to its top-selling drugs from....More>>>

Atara Biotherapeutics: What Q1 2018 Earnings Foretell?

The big money is not in the buying and selling. But in the waiting. – Charlie Munger

Atara Biotherapeutics (NASDAQ:ATRA) is one of the most promising growers that weve encountered thus far. As follows, the company is hitting its growth inflection with a key late-stage T-cell immunotherapeutic (tab-cel, formerly known as ATA-129). In anticipating the strong data reporting, the....More>>>

Sangamo Therapeutics Stock History

If you’ve been following the news lately, you might have heard about gene editing, a process that involves rewriting a person’s DNA to correct genetic disorders, and you’re wondering what all the buzz is about.

While gene editing is getting a lot of attention recently, it’s far from a new idea. Sangamo Therapeutics (NASDAQ:SGMO) has been working on gene-editing research....More>>>

Sangamo Therapeutics Stock History

If you’ve been following the news lately, you might have heard about gene editing, a process that involves rewriting a person’s DNA to correct genetic disorders, and you’re wondering what all the buzz is about.

While gene editing is getting a lot of attention recently, it’s far from a new idea. Sangamo Therapeutics (NASDAQ:SGMO) has been working on gene-editing research....More>>>

Your Daily Pharma Scoop: Biohaven Updates, MEIP Offering, Kite European Expansions

Analysis focus: BHVN

Biohaven Pharmaceuticals (NYSE:BHVN) is a CNS-focused company with a strong pipeline with multiple drug candidates in late stage trials. The company recently announced a number of updates for its pipeline. For its lead candidate, rimegepant from the CGRP receptor antagonist platform, the company will report initial results from a long-term safety study in Q4 2018. In....More>>>